Payment overview · 2025
General Payments
$206.52
9 reported records · 6 companies
Healthcare provider profile · identity verified
Matthew Wade John, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEES SUMMIT, MO · NPI 1841228814
Verified facts
What the public records show
CMS Open Payments records show Matthew Wade John, MD received $206.52 in general payments during 2025 across 9 reported records.
Boston Scientific Corporation accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.03 | 21.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.07 | 19.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.54 | 18.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.98 | 16.9% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $29.83 | 14.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.07 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.52 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $45.03 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 381 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 108 |
| Lisinopril | Lisinopril | 361 | 105 |
| Omeprazole | Omeprazole | 359 | 108 |
| Losartan Potassium | Losartan Potassium | 321 | 96 |
| Metformin Hcl | Metformin Hcl | 280 | 75 |
| Simvastatin | Simvastatin | 247 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 65 |
| Gabapentin | Gabapentin | 233 | 86 |
| Tramadol Hcl | Tramadol Hcl | 207 | 53 |
| Alprazolam | Alprazolam | 205 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 45 |
| Allopurinol | Allopurinol | 156 | 43 |
| Eliquis | Apixaban | 155 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 48 |
| Trazodone Hcl | Trazodone Hcl | 147 | 39 |
| Ozempic | Semaglutide | 144 | 30 |
| Carvedilol | Carvedilol | 124 | 41 |
| Alendronate Sodium | Alendronate Sodium | 122 | 43 |
| Meloxicam | Meloxicam | 118 | 37 |
| Metformin Hcl Er | Metformin Hcl | 113 | 40 |
| Furosemide | Furosemide | 107 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 29 |
| Sertraline Hcl | Sertraline Hcl | 106 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 34 |
| Potassium Chloride | Potassium Chloride | 105 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 36 |
| Celecoxib | Celecoxib | 100 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 31 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Prednisone | Prednisone | 92 | 36 |
| Jardiance | Empagliflozin | 90 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 36 |
| Spironolactone | Spironolactone | 77 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 22 |
| Diazepam | Diazepam | 71 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Lorazepam | Lorazepam | 71 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 71 | suppressed |
| Chlorthalidone | Chlorthalidone | 69 | 22 |
| Pregabalin | Pregabalin | 68 | 17 |
| Glipizide Er | Glipizide | 67 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | suppressed |
| Finasteride | Finasteride | 63 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Lovastatin | Lovastatin | 58 | 19 |
| Baclofen | Baclofen | 55 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 15 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Azithromycin | Azithromycin | 51 | 39 |
| Buspirone Hcl | Buspirone Hcl | 51 | 17 |
| Mounjaro | Tirzepatide | 51 | 12 |
| Clonazepam | Clonazepam | 49 | 12 |
| Estradiol | Estradiol | 48 | 15 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Atenolol | Atenolol | 45 | 13 |
| Trulicity | Dulaglutide | 45 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Famotidine | Famotidine | 44 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 14 |
| Farxiga | Dapagliflozin Propanediol | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Fluconazole | Fluconazole | 38 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 20 |
| Ketoconazole | Ketoconazole | 34 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 26 |
| Azelastine Hcl | Azelastine Hcl | 33 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Nystatin | Nystatin | 31 | 18 |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 12 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Cephalexin | Cephalexin | 28 | 15 |
| Prolia | Denosumab | 28 | 16 |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 13 |
| Naproxen | Naproxen | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Colchicine | Colchicine | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Primidone | Primidone | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.52 · 9 records | Boston Scientific Corporation | ABRYSVO, COMIRNATY, Evoke, GEMTESA, General - Pain Management, PREVNAR 20, QULIPTA, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error